

Comments from Mattias Perjos, President & CEO

### Continued healthy growth – improvements proceeding as planned

“Getinge is continuing to generate growth on a broad front. The order intake increased by slightly more than 10% during the quarter and net sales 6% organically, meaning that we are adjusting our outlook for the full-year to be well within 2-4% organic growth in net sales. The gross margin was negatively impacted by market and product mix effects as a result of the strong sales in primarily emerging markets and in capital goods. This is natural in a growth phase and is expected to support future sales of disposables as the installed base expands. In addition, Surgical Workflows and Life Science increased their net sales at a higher rate than Acute Care Therapies, which also contributed to the Group’s lower gross margin. Operating expenses stabilized after a number of quarters of gradual increases, but we are not ruling out slightly higher operating expenses in future quarters, mainly due to ongoing quality improvements linked to the Consent Decree with the FDA and the need to fill certain positions in the sales and service organization. All in all, I have a confident outlook for the second half of the year with a continued focus on innovation, customers, quality and cost awareness.”

### April – June 2018 in brief

- Order intake increased organically by 10.2%, with a robust performance in capital goods and in emerging markets.
- Net sales increased organically by 6.0% also due to the favorable trend in capital goods and in emerging markets.
- Adjusted EBITA amounted to SEK 538 M (702) with profitability weighed down by lower gross margin due to the product and market mix.
- Currency effects impacted net sales by SEK +40 M, gross profit by SEK -32 M and EBITA by SEK -69 M.
- Adjusted earnings per share amounted to SEK 1.21 (1.62).
- Agreement signed with Brazilian authority, entailing a company fine of SEK 276 M, which is covered by previously communicated provision. An additional tax provision of SEK 64 M has been made for self correction of tax return.

### January – June 2018 in brief

- Order intake increased organically by 6.7%.
- Net sales increased organically by 5.7%.
- Adjusted EBITA amounted to SEK 839 M (1,187).
- Adjusted earnings per share amounted to SEK 1.67 (2.64).
- Provision of SEK 350 M for the ongoing investigations and negotiations in Brazil, which has been communicated earlier.
- Paul Marcun was appointed President Surgical Workflows Business Area and took office end of June.
- Life Science is reported as a new Business Area from January 1, 2018.

### Outlook 2018 (preceding outlook in parentheses)

- Organic sales growth is expected to be well within 2-4% (*slightly positive*) for the full-year 2018.
- Currency transaction effects are expected to have a negative impact of about SEK -175 M (*-150*) on the Group’s 2018 EBIT.

### Summary of financial performance<sup>1)</sup>

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Order intake</b>	<b>6,117</b>	<b>5,523</b>	<b>11,445</b>	<b>10,902</b>	<b>23,228</b>
<i>Organic change, %</i>	<i>10.2</i>	<i>-6.7</i>	<i>6.7</i>	<i>-2.6</i>	<i>2.5</i>
<b>Net sales</b>	<b>5,731</b>	<b>5,369</b>	<b>10,599</b>	<b>10,180</b>	<b>22,495</b>
<i>Organic change, %</i>	<i>6.0</i>	<i>-0.5</i>	<i>5.7</i>	<i>1.0</i>	<i>1.3</i>
<b>Adjusted gross profit</b>	<b>2,844</b>	<b>2,828</b>	<b>5,432</b>	<b>5,438</b>	<b>11,652</b>
<i>Margin, %</i>	<i>49.6</i>	<i>52.7</i>	<i>51.3</i>	<i>53.4</i>	<i>51.8</i>
<b>Adjusted EBITDA</b>	<b>833</b>	<b>997</b>	<b>1,424</b>	<b>1,772</b>	<b>4,285</b>
<i>Margin, %</i>	<i>14.5</i>	<i>18.6</i>	<i>13.4</i>	<i>17.4</i>	<i>19.0</i>
<b>Adjusted EBITA</b>	<b>538</b>	<b>702</b>	<b>839</b>	<b>1,187</b>	<b>3,108</b>
<i>Margin, %</i>	<i>9.4</i>	<i>13.1</i>	<i>7.9</i>	<i>11.7</i>	<i>13.8</i>
<b>Adjusted EBIT</b>	<b>418</b>	<b>553</b>	<b>608</b>	<b>883</b>	<b>2,522</b>
<i>Margin, %</i>	<i>7.3</i>	<i>10.3</i>	<i>5.7</i>	<i>8.7</i>	<i>11.2</i>
<b>Operating profit (EBIT)</b>	<b>405</b>	<b>42</b>	<b>244</b>	<b>344</b>	<b>1,493</b>
<i>Margin, %</i>	<i>7.1</i>	<i>0.8</i>	<i>2.3</i>	<i>3.4</i>	<i>6.6</i>
<b>Profit/loss before tax</b>	<b>331</b>	<b>-116</b>	<b>49</b>	<b>43</b>	<b>933</b>
<b>Net profit/loss for the period</b>	<b>91</b>	<b>-85</b>	<b>-210</b>	<b>32</b>	<b>1,117</b>
<b>Adjusted net profit for the period</b>	<b>340</b>	<b>397</b>	<b>471</b>	<b>647</b>	<b>1,994</b>
<i>Margin, %</i>	<i>5.9</i>	<i>7.4</i>	<i>4.4</i>	<i>6.4</i>	<i>8.9</i>
<b>Adjusted earnings per share, SEK</b>	<b>1.21</b>	<b>1.62</b>	<b>1.67</b>	<b>2.64</b>	<b>7.87</b>
<b>Earnings per share, SEK</b>	<b>0.30</b>	<b>-0.37</b>	<b>-0.83</b>	<b>0.10</b>	<b>4.37</b>
<b>Cash flow from operating activities<sup>2)</sup></b>	<b>401</b>	<b>223</b>	<b>699</b>	<b>1,091</b>	<b>2,763</b>

1) See page 3 for underlying calculations of adjusted performance measures. 2) Cash flow 2017 also includes Arjo, which was distributed to shareholders in December 2017.

Every care has been taken in the translation of this Financial Report. In the event of discrepancies, the Swedish original will supersede the English translation. Unless otherwise stated, all results in this report pertain to the continuing operations, excluding Arjo, which was distributed to shareholders in December 2017.

## Group performance

### Order intake

Apr – Jun 2018

- Organic growth in order intake in all business areas and regions.
- Particularly robust growth in Surgical Workflows in Eastern Europe, Middle East and Africa.
- Acute Care Therapies reports a very strong order intake in APAC, with China performing particularly well in the quarter.
- Very robust growth for Life Science in emerging markets.

Order intake business areas, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
	Acute Care Therapies	3,219		3,109	3.5		6,126
Life Science	576	464	20.3	1,131	1,016	10.6	2,011
Surgical Workflows	2,322	1,950	18.5	4,188	3,802	11.2	8,834
<b>Total</b>	<b>6,117</b>	<b>5,523</b>	<b>10.2</b>	<b>11,445</b>	<b>10,902</b>	<b>6.7</b>	<b>23,228</b>

Order intake regions, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
	Americas	2,319		2,241	5.6		4,491
APAC	1,327	1,190	10.6	2,349	2,118	12.6	4,744
EMEA	2,471	2,092	15.0	4,605	4,267	5.8	9,335
<b>Total</b>	<b>6,117</b>	<b>5,523</b>	<b>10.2</b>	<b>11,445</b>	<b>10,902</b>	<b>6.7</b>	<b>23,228</b>

### Net sales

Apr – Jun 2018


- Organic growth in all business areas.
- Very robust growth in APAC in all business areas.
- Strong performance for Surgical Workplaces and Life Science in EMEA.
- In Americas, Life Science reported healthy growth, while Acute Care Therapies reported weaker sales. One of the reasons was increased competition in covered stents since the second quarter of 2017.
- Sales of capital goods continued to grow at a faster rate than disposables, which contributed to a negative mix effect on the gross margin.

Net sales business areas, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
	Acute Care Therapies	3,148		3,094	1.5		5,999
Life Science	550	406	32.7	992	867	14.0	1,947
Surgical Workflows	2,033	1,869	7.6	3,608	3,394	6.9	8,347
<b>Total</b>	<b>5,731</b>	<b>5,369</b>	<b>6.0</b>	<b>10,599</b>	<b>10,180</b>	<b>5.7</b>	<b>22,495</b>

Net sales regions, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
	Americas	2,273		2,311	0.0		4,413
APAC	1,192	1,009	17.3	2,060	1,858	12.7	4,684
EMEA	2,266	2,049	7.2	4,126	3,875	3.7	8,772
<b>Total</b>	<b>5,731</b>	<b>5,369</b>	<b>6.0</b>	<b>10,599</b>	<b>10,180</b>	<b>5.7</b>	<b>22,495</b>

Net sales specified by capital goods and consumables, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
	Capital goods	2,333		2,056	12.7		4,060
Consumables	3,398	3,313	1.8	6,539	6,484	2.7	12,906
<b>Total</b>	<b>5,731</b>	<b>5,369</b>	<b>6.0</b>	<b>10,599</b>	<b>10,180</b>	<b>5.7</b>	<b>22,495</b>

### Net sales – bridge between Apr-Jun 2017 and Apr-Jun 2018



- Net sales increased organically by 6.7% in the quarter.
- Exchange rates impacted sales by +0.7% compared with Q2 2017.
- Volume, product and market mix effects impacted sales by +6.0% compared with Q2 2017.

## Underlying earnings trend

- Currency effects impacted net sales by SEK +40 M, gross profit by SEK -32 M and EBITA by SEK -69 M.
- The gross margin is negatively impacted by currency, product and market mix. Growth was particularly robust in capital goods and in emerging markets during the quarter. In addition, sales increased more in Surgical Workflows and Life Science than in Acute Care Therapies (which reported a higher gross margin).
- Operating expenses were in line with outcome in the first quarter of 2018, but were higher compared with the second quarter of 2017. This was mainly related to increased investment in sales, quality and R&D and negative currency effects. Furthermore, continuing Group-wide expenses after the distribution of Arjo negatively affected profitability.
- The tax expense for the period was impacted by a tax provision of SEK 64 M related to self correction of tax return due to non-deductible costs attributable to ongoing investigations in Brazil and SEK 88 M in revaluation of capitalized tax loss carryforwards due to the tax rate change in Sweden.

- Adjusted EBITA in Acute Care Therapies fell by SEK -42 M, mainly due to a negative currency effect of SEK -29 M and lower gross margin.
- In Life Science, adjusted EBITA declined by SEK -12 M, of which SEK -8 M was attributable to negative currency effects and the remainder mainly due to lower gross margin and higher operating expenses attributable to building up the business area.
- Adjusted EBITA in Surgical Workflows fell by SEK -88 M, primarily related to lower gross margin, negative currency effects of SEK 32 M and higher operating expenses as a result of continuing costs after the distribution of Arjo.

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Net sales	5,731	5,369	10,599	10,180	22,495
<b>Adjusted gross profit</b>	<b>2,844</b>	<b>2,828</b>	<b>5,432</b>	<b>5,438</b>	<b>11,652</b>
Margin, %	49.6	52.7	51.3	53.4	51.8
Adjusted operating expenses	-2,011	-1,831	-4,008	-3,666	-7,367
<b>Adjusted EBITDA</b>	<b>833</b>	<b>997</b>	<b>1,424</b>	<b>1,772</b>	<b>4,285</b>
Margin, %	14.5	18.6	13.4	17.4	19.0
Depreciation, amortization and write-downs of tangible and intangible assets <sup>1)</sup>	-295	-295	-585	-585	-1,177
<b>Adjusted EBITA</b>	<b>538</b>	<b>702</b>	<b>839</b>	<b>1,187</b>	<b>3,108</b>
Margin, %	9.4	13.1	7.9	11.7	13.8
<b>A</b>					
Amortization and write-down of acquired intangible assets <sup>1)</sup>	-120	-149	-231	-304	-586
<b>Adjusted EBIT</b>	<b>418</b>	<b>553</b>	<b>608</b>	<b>883</b>	<b>2,522</b>
Margin, %	7.3	10.3	5.7	8.7	11.2
<b>B</b> Acquisition and restructuring costs	-13	-511	-14	-539	-763
<b>C</b> Other items affecting comparability <sup>2)</sup>	-	-	-350	-	-266
<b>Operating profit (EBIT)</b>	<b>405</b>	<b>42</b>	<b>244</b>	<b>344</b>	<b>1,493</b>
Net financial items	-74	-158	-195	-301	-560
<b>Profit/loss before tax</b>	<b>331</b>	<b>-116</b>	<b>49</b>	<b>43</b>	<b>933</b>
<b>Adjusted profit before tax</b> (adjusted for A, B and C)	<b>464</b>	<b>544</b>	<b>644</b>	<b>886</b>	<b>2,548</b>
Margin, %	8.1	10.1	6.1	8.7	11.3
Taxes	-240	31	-259	-11	184
<b>D</b> Adjustment of tax <sup>2)</sup>	116	-178	86	-228	-738
<b>Adjusted net profit for the period</b> (adjusted for A, B, C and D)	<b>340</b>	<b>397</b>	<b>471</b>	<b>647</b>	<b>1,994</b>
Margin, %	5.9	7.4	4.4	6.4	8.9
Of which, attributable to Parent Company's shareholders	330	392	455	638	1,973
<b>Average number of shares, thousands</b>	<b>272,370</b>	<b>241,780</b>	<b>272,370</b>	<b>241,780</b>	<b>250,720</b>
<b>Adjusted earnings per share, SEK</b> (adjusted for A, B, C and D)	<b>1.21</b>	<b>1.62</b>	<b>1.67</b>	<b>2.64</b>	<b>7.87</b>


1) Excluding items affecting comparability (see Note 3 for depreciation, amortization and write-downs). 2) See Note 5.

## Adjusted EBITA per business area <sup>1)</sup>

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Acute Care Therapies</b>	<b>596</b>	<b>638</b>	<b>1,066</b>	<b>1,195</b>	<b>2,500</b>
Margin, %	18.9	20.6	17.8	20.2	20.5
<b>Life Science</b>	<b>52</b>	<b>64</b>	<b>109</b>	<b>168</b>	<b>369</b>
Margin, %	9.5	15.8	11.0	19.4	19.0
<b>Surgical Workflows</b>	<b>-39</b>	<b>49</b>	<b>-204</b>	<b>-78</b>	<b>445</b>
Margin, %	-1.9	2.6	-5.7	-2.3	5.3
Group functions and other (incl. eliminations)	-71	-49	-132	-98	-206
<b>Total</b>	<b>538</b>	<b>702</b>	<b>839</b>	<b>1,187</b>	<b>3,108</b>
Margin, %	9.4	13.1	7.9	11.7	13.8

1) See Note 3 for depreciation, amortization and write-downs and Note 5 for other items affecting comparability

## Adjusted EBITA – bridge between Apr-Jun 2017 and Apr-Jun 2018



## Adjusted operating expenses


(excluding depreciation, amortization and write-downs and other items affecting comparability)<sup>1)</sup>

- Adjusted operating expenses remained higher than in the year-earlier period in 2017 due in part to investments in quality, sales and R&D and in part to continuing costs after the distribution of Arjo.
- Adjusted operating expenses rose by 0.7% or SEK 14 M compared with the first quarter of 2018.

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Selling expenses	-1,141	-1,084	-2,260	-2,164	-4,319
Administrative expenses	-680	-581	-1,346	-1,233	-2,427
Research and development costs	-177	-150	-347	-272	-568
Other operating income and expenses	-13	-16	-55	3	-53
<b>Total</b>	<b>-2,011</b>	<b>-1,831</b>	<b>-4,008</b>	<b>-3,666</b>	<b>-7,367</b>

1) See Note 3 for depreciation and write-downs and Note 5 for other items affecting comparability.


## Adjusted EBITA – bridge between Apr-Jun 2017 and Apr-Jun 2018



## Currency impact

- Net sales for the quarter were positively impacted by SEK 40 M in translation effects. Support mainly derived from the EUR, which offset the negative effect of the USD.
- EBIT for the quarter was impacted by translation effects of SEK -29 M and transaction effects of SEK -39 M.

SEK M	Apr-Jun 2018	Jan-Jun 2018
Net sales	40	-160
Gross profit	-32	-210
EBITDA	-61	-186
EBITA	-69	-194
Operating profit (EBIT)	-68	-183



## Cash flow and financial position<sup>1)</sup>

- Working capital was impacted by the build-up of inventories, due to a high level of order intake.
- Payment of company fine of SEK 276 M related to ongoing investigations in Brazil is planned for the fourth quarter of 2018.

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Cash flow before changes in working capital	440	925	712	1,719	3,653
Changes in working capital	-39	-702	-13	-628	-890
Net investments in non-current assets	-354	-390	-653	-756	-1,633
<b>Cash flow after net investments</b>	<b>47</b>	<b>-167</b>	<b>46</b>	<b>335</b>	<b>1,130</b>
Net interest-bearing debt at end of the period			13,845	22,666	12,792
<i>In relation to adjusted EBITDA<sup>2)</sup> R12M, multiple</i>			3.5	N/A	3.0

1) Cash flows for 2017 also include Arjo, which was distributed to shareholders in December 2017. 2) See Note 5 and Note 7 (Alternative performance measures).

- Gross expenses for R&D increased by 16.5%.
- Capitalized development costs rose by 14.9%
- Research and development costs increased by 17.9% net.

## Research and development

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>R&amp;D costs, gross</b>	-346	-297	-666	-572	-1,123
<i>In relation to net sales, %</i>	6.0	5.5	6.3	5.6	5.0
<b>Capitalized development costs</b>	162	141	305	287	529
<i>In relation to net sales, %</i>	2.8	2.6	2.9	2.8	2.4
<b>Research and development costs, net</b>	<b>-184</b>	<b>-156</b>	<b>-361</b>	<b>-285</b>	<b>-594</b>
<b>Amortization and write-downs of capitalized R&amp;D</b>	<b>-120</b>	<b>-119</b>	<b>-243</b>	<b>-238</b>	<b>-675</b>
<i>Of which write-downs</i>	-	-	-	-	-193

- Improvements continue to take place in Hechingen in accordance with the revised plan from 2017.
- The unutilized provision totaled SEK 498 M at the end of the quarter, compared with SEK 536 M at the start of the quarter.

## Update regarding Consent Decree with the FDA

SEK M	Jun 30 2018	Jun 30 2017	Dec 31 2017
<b>Provision at beginning of period</b>	<b>556</b>	<b>371</b>	<b>371</b>
Used amount	-92	-141	-296
Provisions	-	488	488
Translation differences	34	-8	-7
<b>Provision at close of period</b>	<b>498</b>	<b>710</b>	<b>556</b>

- The Consent Decree with the FDA was signed in February 2015 and originally encompassed a total of four production units in the US and Germany.
- Improvement plans for the necessary corrections have been prepared for each unit. Necessary corrections according to the established plan at the two production units in the US are expected to be completed by the end of 2018. This work is expected to take longer at Hechingen.
- Getinge committed SEK 995 M in 2014 related to the remediation program for strengthening the former Medical Systems' quality management system, and in 2016 and 2017 SEK 400 M and SEK 488 M, respectively, were committed for the same purpose. The total cost of the remediation program thus amounted to SEK 1,983 M at the end the second quarter of 2018.

## Other key events during the quarter

Getinge reached an agreement with the Brazilian Federal Public Prosecutor's Office (Ministério Público Federal) on a Leniency Agreement mainly related to the manipulation of tender procedures in Brazil. These cases mainly relate to 2004-2015, and primarily involve Getinge's Brazilian subsidiaries Maquet Cardiopulmonary do Brasil Indústria e Comércio Ltda and Maquet do Brasil Equipamentos Médicos Ltda.

The agreement entails that Getinge will pay a company fine corresponding to approximately SEK 276 M (BRL 121.8 M). The amount is included in the previous provision\* made by Getinge for costs related to the Brazilian investigations and will not affect operating profit further. The fine will be paid during the fourth quarter of 2018. As a result of the fine, Getinge has made a provision of SEK 64 M for self correction of tax for non-deductible costs.

Getinge is currently in negotiations with other Brazilian authorities, which are expected to be completed in 2018.

It cannot be ruled out that any further agreements with authorities may have a material impact on Getinge's earnings and financial position, in addition to provisions made.

\*Getinge has made two provisions for a total of SEK 419 M for costs related to the investigations in Brazil. SEK 69 M in the fourth quarter of 2017 and SEK 350 M in the first quarter of 2018.

## Acute Care Therapies

Acute Care Therapies offers solutions for life support in acute health conditions. The offering includes solutions for cardiac, pulmonary and vascular therapies and a broad selection of products and therapies for intensive care. The addressable market amounted to SEK 85 billion with expected organic growth of 2-4% per year to 2020.

### Order intake and net sales

- Healthy order intake in heart-lung machines, ventilators and intra-aortic balloon pumps (IABP).
- Very robust growth in APAC, with China and India performing strongly.

- High net sales in heart-lung machines and intra-aortic balloon pumps.
- Healthy growth in heart-lung machines in East Asia and Latin America
- Lower sales of covered stents in the USA as a result of increased competition in this area since the second quarter of 2017. However, this decline is leveling off.
- Sales of capital goods declined slightly compared with the second quarter of 2017.

- Lower gross margin due to mix effects, primarily in the form of higher sales in emerging markets and lower sales of stents in the US. In addition, currency effects were negative.
- Operating profit was impacted by lower gross margin and higher quality costs. Additional costs cannot be ruled out in autumn 2018, mainly due to high intensity in improvements according to the Consent Decree with the FDA.
- Currency effects impacted sales by SEK +5 M, gross profit by SEK -14 M and EBITA by SEK -29 M.

Order intake regions, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
Americas	1,563	1,565	2.0	2,988	3,139	0.6	6,234
APAC	647	567	13.7	1,154	1,024	15.2	2,191
EMEA	1,009	977	0.0	1,984	1,921	1.2	3,958
<b>Total</b>	<b>3,219</b>	<b>3,109</b>	<b>3.5</b>	<b>6,126</b>	<b>6,084</b>	<b>3.2</b>	<b>12,383</b>

Net sales regions, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
Americas	1,552	1,633	-3.3	3,024	3,172	0.6	6,263
APAC	643	542	17.9	1,139	999	16.2	2,227
EMEA	953	919	0.4	1,836	1,748	2.2	3,711
<b>Total</b>	<b>3,148</b>	<b>3,094</b>	<b>1.5</b>	<b>5,999</b>	<b>5,919</b>	<b>3.7</b>	<b>12,201</b>

Net sales specified by capital goods and consumables, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
Capital goods	770	790	-2.2	1,400	1,385	3.3	3,289
Consumables	2,378	2,304	2.8	4,599	4,534	3.9	8,912
<b>Total</b>	<b>3,148</b>	<b>3,094</b>	<b>1.5</b>	<b>5,999</b>	<b>5,919</b>	<b>3.7</b>	<b>12,201</b>

### Underlying earnings trend<sup>1)</sup>

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Net sales</b>	<b>3,148</b>	<b>3,094</b>	<b>5,999</b>	<b>5,919</b>	<b>12,201</b>
<b>Adjusted gross profit</b>	<b>1,856</b>	<b>1,886</b>	<b>3,609</b>	<b>3,639</b>	<b>7,403</b>
Margin, %	59.0	61.0	60.2	61.5	60.7
<b>Adjusted EBITDA</b>	<b>769</b>	<b>809</b>	<b>1,411</b>	<b>1,533</b>	<b>3,174</b>
Margin, %	24.4	26.1	23.5	25.9	26.0
Depreciation, amortization and write-downs of tangible and intangible assets	-173	-171	-345	-338	-674
<b>Adjusted EBITA</b>	<b>596</b>	<b>638</b>	<b>1,066</b>	<b>1,195</b>	<b>2,500</b>
Margin, %	18.9	20.6	17.8	20.2	20.5

1) See Note 3 for depreciation, amortization and write-downs, Note 5 for other items affecting comparability and Note 7 (alternative performance measures).

### Key events in the business area

- A milestone was achieved in the quarter when CE marking was obtained for the software that enables high frequency oscillation (HFO) in Getinge's Servo-n ventilator. It means that the company becomes a full-service supplier to the key market for ventilators in neonatal care.
- With the launch of Flow-c, Getinge took a giant leap into the mid-segment of the anesthesia market. The reception from customers has been very positive.
- A first ever randomized multicenter international trial on extracorporeal membrane oxygenation (ECMO) to rescue lung injury in severe ARDS (EOLIA) was published in the prestigious *New England Journal of Medicine*. The results demonstrated that the care of the patient with appropriate ventilation management combined with planned early ECMO is an effective strategy for treatment of patients suffering from severe acute respiratory distress syndrome (ARDS).
- Getinge's market-leading CARDIOSAVE intra-aortic balloon pump received industry approval under the EN 60601 standard on the safety and essential performance of medical electrical equipment, a requirement for all markets in the EU.

## Life Science

Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in biopharmaceutical production, biomedical research, medical device manufacturing, and laboratory applications. The addressable market amounted to SEK 23 billion with expected organic growth of 3-5% per year to 2020.

### Order intake and net sales

- Very robust growth in all regions and across the product portfolio.
- Particularly high growth in disinfection and sterilizers.

Order intake regions, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
Americas	193	150	27.9	407	341	24.0	673
APAC	120	83	40.0	206	192	6.8	335
EMEA	263	231	8.2	518	483	2.6	1,003
<b>Total</b>	<b>576</b>	<b>464</b>	<b>20.3</b>	<b>1,131</b>	<b>1,016</b>	<b>10.6</b>	<b>2,011</b>

- Very robust growth in all regions and product categories.
- EMEA reported the largest increase in sales in absolute terms, primarily due to four major projects in the UK and Germany.
- Growth in capital goods continued to increase at a faster rate than consumables.

Net sales regions, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
Americas	203	160	27.0	375	348	11.7	718
APAC	64	37	74.0	112	105	7.6	328
EMEA	283	209	29.9	505	414	17.6	901
<b>Total</b>	<b>550</b>	<b>406</b>	<b>32.7</b>	<b>992</b>	<b>867</b>	<b>14.0</b>	<b>1,947</b>

Net sales specified by capital goods and consumables, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
Capital goods	349	246	38.8	607	500	20.5	1,183
Consumables	201	160	23.3	385	367	5.2	764
<b>Total</b>	<b>550</b>	<b>406</b>	<b>32.7</b>	<b>992</b>	<b>867</b>	<b>14.0</b>	<b>1,947</b>

### Underlying earnings trend<sup>1)</sup>

- The gross margin was adversely impacted by product mix effects with capital goods delivering significant growth. Currency effects were also negative.
- Operating profit was negatively affected by the lower gross margin and higher operating expenses in sales and administration connected with the establishment of the business area. The business area was also adversely impacted by continuing costs after the distribution of Arjo.
- Currency effects impacted sales by SEK +12 M, gross profit by SEK -4 M and EBITA by SEK -8 M.

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Net sales</b>	<b>550</b>	<b>406</b>	<b>992</b>	<b>867</b>	<b>1,947</b>
<b>Adjusted gross profit</b>	<b>196</b>	<b>172</b>	<b>382</b>	<b>359</b>	<b>790</b>
Margin, %	35.6	42.4	38.5	41.4	40.6
<b>Adjusted EBITDA</b>	<b>70</b>	<b>79</b>	<b>145</b>	<b>199</b>	<b>435</b>
Margin, %	12.7	19.5	14.6	23.0	22.3
Depreciation, amortization and write-downs of tangible and intangible assets	-18	-15	-36	-31	-66
<b>Adjusted EBITA</b>	<b>52</b>	<b>64</b>	<b>109</b>	<b>168</b>	<b>369</b>
Margin, %	9.5	15.8	11.0	19.4	19.0

1) See Note 3 for depreciation, amortization and write-downs, Note 5 for other items affecting comparability and Note 7 (alternative performance measures).

### Key events in the business area

- Launch of Getinge Steam Sterilizer (GSS). This new series of steam sterilizers has been developed to meet the strict requirements from the growing segments of biopharmaceutical production and biomedical research. The launch took place at theACHEMA exhibition in Frankfurt in June and the first deliveries to customers have already been made.

## Surgical Workflows

*Surgical Workflows offers products and services for efficient disinfection and sterilization of instruments used in operations, operating tables and other high-quality hardware for operating rooms and advanced IT systems for efficient and secure hospital workflows. The addressable market amounted to SEK 62 billion with expected organic growth of 2-4% per year to 2020.*

### Order intake and net sales

- Very high order intake, with growth in all regions.
- Particularly strong performance in Infection Control and Surgical Workplaces.

Order intake regions, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
Americas	563	526	9.8	1,096	1,037	11.4	2,242
APAC	560	540	2.7	989	902	10.8	2,218
EMEA	1,199	884	33.4	2,103	1,863	11.3	4,374
<b>Total</b>	<b>2,322</b>	<b>1,950</b>	<b>18.5</b>	<b>4,188</b>	<b>3,802</b>	<b>11.2</b>	<b>8,834</b>

- Very high net sales, with growth in all regions.
- Particularly strong trend in Surgical Workplaces, with success in sales in emerging markets and in major projects.
- Growth in capital goods is continuing to increase at a fast rate.

Net sales regions, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
Americas	518	518	1.9	1,014	927	15.0	2,058
APAC	485	430	11.8	809	754	8.6	2,129
EMEA	1,030	921	8.8	1,785	1,713	1.9	4,160
<b>Total</b>	<b>2,033</b>	<b>1,869</b>	<b>7.6</b>	<b>3,608</b>	<b>3,394</b>	<b>6.9</b>	<b>8,347</b>

Net sales specified by capital goods and consumables, SEK M	Apr-Jun 2018	Apr-Jun 2017	Org Δ, %	Jan-Jun 2018	Jan-Jun 2017	Org Δ, %	Jan-Dec 2017
Capital goods	1,214	1,020	18.0	2,053	1,811	14.1	5,117
Consumables	819	849	-4.9	1,555	1,583	-1.2	3,230
<b>Total</b>	<b>2,033</b>	<b>1,869</b>	<b>7.6</b>	<b>3,608</b>	<b>3,394</b>	<b>6.9</b>	<b>8,347</b>

### Underlying earnings trend<sup>1)</sup>

- The gross margin was negatively impacted by currency effects, the product and market mix, with higher sales in emerging markets and in capital goods with lower margins. Lower sales of disposables that include service were primarily due to Infection Control and IWS, which both reported a strong performance in the year-earlier period.
- Operating profit was negatively affected by the lower gross margin and higher operating expenses, primarily related to increased sales resources in the US, higher logistics costs and continuing costs following the spin-off of Arjo.
- Currency effects impacted sales by SEK +23 M, gross profit by SEK -14 M and EBITA by SEK -32 M.

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Net sales</b>	<b>2,033</b>	<b>1,869</b>	<b>3,608</b>	<b>3,394</b>	<b>8,347</b>
<b>Adjusted gross profit</b>	<b>792</b>	<b>770</b>	<b>1,441</b>	<b>1,440</b>	<b>3,459</b>
Margin, %	39.0	41.2	39.9	42.4	41.4
<b>Adjusted EBITDA</b>	<b>63</b>	<b>157</b>	<b>-3</b>	<b>136</b>	<b>878</b>
Margin, %	3.1	8.4	-0.1	4.0	10.5
Depreciation, amortization and write-downs of tangible and intangible assets	-102	-108	-201	-214	-433
<b>Adjusted EBITA</b>	<b>-39</b>	<b>49</b>	<b>-204</b>	<b>-78</b>	<b>445</b>
Margin, %	-1.9	2.6	-5.7	-2.3	5.3

1) See Note 3 for depreciation, amortization and write-downs, Note 5 for other items affecting comparability and Note 7 (alternative performance measures).

### Key events in the business area

- Launch of the Maquet Yuno II operating table for optimum results in open or minimally invasive interventions. The table can be configured for any discipline, maximizing the functionality and utilization of the operating room.
- Launch of the new Maquet Meera ST operating table, offering the same advantages as Maquet Meera, in addition to functionality for gynecological and urological procedures. Maquet Meera ST offers high functionality for clinics that perform few or no such operations.
- Launch of a carbon fiber table component for the Maquet Otesus and Maquet Yuno II for procedures requiring unrestricted transparency when using a scanner, for example, pelvic, cardiovascular, orthopaedic, traumatology and spinal surgery.



## Other information

### Risk management

#### Healthcare reimbursement system

Political decisions represent the single greatest market risk to Getinge Group. Changes to the healthcare reimbursement system can have a major impact on individual markets by reducing or deferring grants. Since Getinge is active in a large number of geographical markets, the risk for the Group as a whole is limited.

#### Customers

Activities conducted by Getinge's customers are generally financed directly or indirectly by public funds and ability to pay is usually very solid, although payment behavior can vary between different countries. All transactions outside the OECD area are covered by payment guarantees, unless the customer's ability to pay is well documented.

#### Authorities and control bodies

Parts of Getinge's operations and product range are covered by legislation stipulating rigorous assessments, quality control and documentation. It cannot be ruled out that Getinge's operations, financial position and earnings may be negatively impacted by difficulties in complying with current regulations and requirements of authorities and control bodies or changes to such regulations and requirements. To limit these risks to the greatest possible extent, Getinge conducts extensive work focused on quality and regulatory issues and every business area assumes overall responsibility for quality and regulatory issues. The majority of the Group's production facilities are certified according to the medical device quality standard ISO 13485 and/or the general quality standard ISO 9001. Getinge is also, and may become in the future, involved in government investigations, disputes and similar proceedings within the framework of its other business operations concerning such issues as the environment, tax and competition. Since Getinge operates in a global environment, the company is also exposed to local business risks, such as corruption and restrictions on trade. To minimize the risk of being subject to such investigations, disputes and proceedings, Getinge works actively on developing, implementing and maintaining policies and systems for ensuring compliance with applicable rules and regulations.

#### Research and development

Getinge's future growth also depends on the company's ability to develop new and successful products. Research and development efforts are costly and it is impossible to guarantee that developed products will be commercially successful. As a means of maximizing the return on research and development efforts, the Group has a very structured selection and planning process to ensure that the Group prioritizes correctly when choosing which potential projects to pursue. This process includes careful analyses of the market, technological progress, choice of production method and selection of subcontractors. The development work is conducted in a structured manner and each project undergoes a number of fixed control points.

#### Product liability and damage claims

Healthcare suppliers run a risk, like other players in the healthcare industry, of being subject to claims relating to product liability and other legal claims. Such claims can involve large amounts and significant legal expenses. Getinge cannot provide any guarantees that its operations will not be subject to compensation claims. Getinge carries the customary indemnity and product liability insurance, but there is a risk that the protection Getinge receives through its insurance policies would be limited for reasons such as amount limits and requirements to pay deductibles.

#### Protection of intellectual property

Getinge is a market leader in the areas in which it operates and invests significant amounts in product development. To secure returns on these investments, Getinge actively upholds its rights and monitors competitors' activities closely. If required, Getinge will protect its intellectual property rights through legal processes.

### Financial risk management

Getinge is exposed to a number of financial risks in its operations. Financial risks principally pertain to risks related to currency and interest-rate risks, as well as credit risks. Risk management is regulated by the finance policy adopted by the Board. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the treasury function. The main financial risks to which the Group is exposed are currency risks, interest-rate risks and credit and counterparty risks.

### Seasonal variations

Getinge's earnings are affected by seasonal variations. The second quarter is normally weak in relation to the remainder of the fiscal year. The third and particularly fourth quarters are usually the Group's strongest quarters.

### Transactions with related parties

Following the distribution of Arjo in December 2017, Getinge carried out normal commercial transactions

with Arjo for the sale and purchase of goods and services. In addition, no other significant transactions with related parties occurred during the period other than transactions with subsidiaries.

### Forward-looking information

This report contains forward-looking information based on the current expectations of company management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding finances, market and competition, changes in legal and regulatory requirements and other political measures, and fluctuations in exchange rates.

### Getinge's financial targets

- Average annual organic growth in net sales: 2-4%
- Average earnings per share growth: >10%
- Getinge's dividend policy is to pay dividends of 30-50% of net profit to shareholders.

## Assurance

The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.

**Gothenburg, July 17, 2018**

**Carl Bennet**  
Chairman

**Johan Bygge**

**Cecilia Daun Wennborg**

**Barbro Fridén**

**Dan Frohm**

**Sofia Hasselberg**

**Peter Jörmalm**

**Rickard Karlsson**

**Johan Malmquist**

**Mattias Perjos**  
President & CEO

**Malin Persson**

**Johan Stern**  
Vice Chairman

*This interim report is unaudited.*

# Consolidated financial statements

## Consolidated income statement

SEK M	Note	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Net sales	2	5,731	5,369	10,599	10,180	22,495
Cost of goods sold	3	-3,077	-2,725	-5,541	-5,108	-11,783
<b>Gross profit</b>	2	<b>2,654</b>	<b>2,644</b>	<b>5,058</b>	<b>5,072</b>	<b>10,712</b>
Selling expenses	3	-1,279	-1,254	-2,527	-2,506	-4,980
Administrative expenses	3	-760	-665	-1,507	-1,401	-2,760
Research and development costs		-184	-156	-361	-285	-594
Acquisition expenses		-1	-2	-2	-3	-4
Restructuring costs		-12	-509	-12	-536	-759
Other operating income and expenses <sup>1)</sup>		-13	-16	-405	3	-122
<b>Operating profit (EBIT)</b>	2.3	<b>405</b>	<b>42</b>	<b>244</b>	<b>344</b>	<b>1,493</b>
Net financial items	2	-74	-158	-195	-301	-560
<b>Profit/loss after financial items</b>	2	<b>331</b>	<b>-116</b>	<b>49</b>	<b>43</b>	<b>933</b>
Taxes		-240	31	-259	-11	184
<b>Net profit/loss for the period from continuing operations</b>		<b>91</b>	<b>-85</b>	<b>-210</b>	<b>32</b>	<b>1,117</b>
Net profit for the period from discontinued operations <sup>2)</sup>	9	-	92	-	256	280
<b>Net profit/loss for the period from continuing and discontinued operations</b>		<b>91</b>	<b>7</b>	<b>-210</b>	<b>288</b>	<b>1,397</b>
<b>Attributable to:</b>						
<b>Parent Company shareholders</b>						
Profit/loss from continuing operations		81	-90	-226	23	1,096
Profit from discontinued operations		-	92	-	256	280
<b>Profit/loss from continuing and discontinued operations</b>		<b>81</b>	<b>2</b>	<b>-226</b>	<b>279</b>	<b>1,376</b>
<b>Non-controlling interests</b>						
Profit/loss from continuing operations		10	5	16	9	21
Profit from discontinued operations		-	-	-	-	-
<b>Profit from continuing and discontinued operations</b>		<b>10</b>	<b>5</b>	<b>16</b>	<b>9</b>	<b>21</b>
<b>Earnings per share, SEK<sup>3</sup></b>		<b>0.30</b>	<b>0.01</b>	<b>-0.83</b>	<b>1.15</b>	<b>5.49</b>
Of which, continuing operations, SEK		0.30	-0.37	-0.83	0.10	4.37
Of which, discontinued operations, SEK		-	0.38	-	1.05	1.12
Weighted average number of shares for calculation of earnings per share (000s) <sup>4)</sup>		272,370	241,780	272,370	241,780	250,720

1) Of which SEK -350 M is related to ongoing investigations in Brazil (2018)

2) The shares in Arjo were distributed to Getinge's shareholders in December 2017 and in this report Arjo is recognized separately as a discontinued operation in accordance with IFRS 5

3) Before and after dilution

4) Adjusted for bonus issue effect of the rights issue

## Consolidated statement of comprehensive income

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Net profit/loss for the period from continuing and discontinued operations</b>	<b>91</b>	<b>7</b>	<b>-210</b>	<b>288</b>	<b>1,397</b>
<b>Other comprehensive income</b>					
<b>Items that cannot be restated in profit for the period</b>					
Actuarial gains/losses pertaining to defined-benefit pension plans	0	122	0	122	179
Tax attributable to items that cannot be restated in profit	0	-47	0	-47	-159
<b>Items that can later be restated in profit for the period</b>					
Translation differences and hedging of net investments	964	-676	1,431	-777	-762
Cash flow hedges	-192	201	-156	335	561
Reversal of translation differences and hedges, discontinued operations	-	-	-	-	-127
Tax attributable to items that can be restated in profit	153	-193	207	-300	-448
<b>Other comprehensive income for the period, net after tax</b>	<b>925</b>	<b>-593</b>	<b>1,482</b>	<b>-667</b>	<b>-756</b>
<b>Total comprehensive income for the period</b>	<b>1,016</b>	<b>-586</b>	<b>1,272</b>	<b>-379</b>	<b>641</b>
<b>Comprehensive income attributable to:</b>					
Parent Company shareholders	1,001	-594	1,231	-391	609
Non-controlling interests	15	8	41	12	32

## Consolidated balance sheet

SEK M	Note	June 30 2018	June 30 2017	December 31 2017
<b>Assets</b>				
Intangible assets		24,522	30,463	23,045
Tangible assets		3,102	4,155	2,911
Financial assets		1,847	1,391	1,586
Inventories		5,689	6,188	4,879
Accounts receivable		5,100	6,694	6,067
Other current receivables		2,265	2,546	2,088
Cash and cash equivalents	6	939	1,400	1,526
<b>Total assets</b>		<b>43,464</b>	<b>52,837</b>	<b>42,102</b>
<b>Equity and liabilities</b>				
Equity		20,668	20,060	19,806
Provisions for pensions, interest-bearing	6	3,222	3,169	3,081
Other interest-bearing liabilities	6	11,562	20,897	11,237
Other provisions		2,344	2,157	2,202
Accounts payable		1,581	1,839	2,025
Other non-interest-bearing liabilities		4,087	4,715	3,751
<b>Total equity and liabilities</b>		<b>43,464</b>	<b>52,837</b>	<b>42,102</b>

## Changes in equity for the Group

SEK M	Share capital	Other capital provided	Reserves <sup>1)</sup>	Retained earnings	Total	Non-controlling interests	Total equity
<b>Opening balance at January 1, 2017</b>	<b>119</b>	<b>5,960</b>	<b>955</b>	<b>13,474</b>	<b>20,508</b>	<b>408</b>	<b>20,916</b>
Total comprehensive income for the period	-	-	-787	1,396	609	32	641
Share-based remuneration	-	-	-	-4	-4	-	-4
Dividend	-	-	-	-477	-477	-18	-495
Rights Issue <sup>2)</sup>	17	4,264	-	-	4,281	-	4,281
Distribution of Arjo <sup>3)</sup>	-	-3,435	-	-2,098	-5,533	-	-5,533
<b>Closing balance at December 31, 2017</b>	<b>136</b>	<b>6,789</b>	<b>168</b>	<b>12,291</b>	<b>19,384</b>	<b>422</b>	<b>19,806</b>
<b>Opening balance at January 1, 2018</b>	<b>136</b>	<b>6,789</b>	<b>168</b>	<b>12,291</b>	<b>19,384</b>	<b>422</b>	<b>19,806</b>
Total comprehensive income for the period	-	-	1,457	-226	1,231	41	1,272
Share-based remuneration	-	-	-	-1	-1	-	-1
Dividend	-	-	-	-409	-409	-	-409
<b>Closing balance at June 30, 2018</b>	<b>136</b>	<b>6,789</b>	<b>1,625</b>	<b>11,655</b>	<b>20,205</b>	<b>463</b>	<b>20,688</b>

1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences.

2) After deductions for transaction costs and taking tax effects into consideration.

3) Including transaction costs and taxes.

## Consolidated cash flow statement

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Operating activities</b>					
Operating profit (EBIT) for continuing operations	405	42	244	344	1,493
Operating profit (EBIT) for discontinued operations	-	120	-	358	294
Add-back of depreciation, amortization and write-downs	415	605	816	1,271	2,609
Other non-cash items	7	11	362	15	51
Add-back of restructuring costs <sup>1)</sup>	12	523	12	551	887
Paid restructuring costs	-64	-142	-109	-257	-539
Financial items	-58	-153	-168	-310	-663
Taxes paid	-277	-81	-445	-253	-479
<b>Cash flow before changes in working capital</b>	<b>440</b>	<b>925</b>	<b>712</b>	<b>1,719</b>	<b>3,653</b>
<b>Changes in working capital</b>					
Inventories	-60	-492	-604	-1,050	-910
Current receivables	138	-152	1,293	821	-653
Current liabilities	-117	-58	-702	-399	673
<b>Cash flow from operating activities</b>	<b>401</b>	<b>223</b>	<b>699</b>	<b>1,091</b>	<b>2,763</b>
<b>Investing activities</b>					
Acquired operations	-4	-41	-4	-81	-81
Investments in intangible assets and tangible assets	-377	-397	-677	-781	-1,663
Divestment of non-current assets	23	7	24	25	30
<b>Cash flow from investing activities</b>	<b>-358</b>	<b>-431</b>	<b>-657</b>	<b>-837</b>	<b>-1,714</b>
<b>Financing activities</b>					
Change in interest-bearing liabilities	253	-224	-275	-46	-4,276
Change in interest-bearing receivables	-1	39	9	15	-56
Distribution of Arjo	-	-	-	-	-623
Dividend paid	-409	-477	-409	-477	-495
Rights issue	-	-	-	-	4,281
<b>Cash flow from financing activities</b>	<b>-157</b>	<b>-662</b>	<b>-675</b>	<b>-508</b>	<b>-1,169</b>
<b>Cash flow for the period</b>	<b>-114</b>	<b>-870</b>	<b>-633</b>	<b>-254</b>	<b>-120</b>
Cash and cash equivalents at the beginning of the period	1,037	2,334	1,526	1,680	1,680
Translation differences	16	-64	46	-26	-34
<b>Cash and cash equivalents at the end of the period</b>	<b>939</b>	<b>1,400</b>	<b>939</b>	<b>1,400</b>	<b>1,526</b>

1) Excluding write-downs on non-current assets

## Note 1 Accounting policies

---

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company, the report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2. The accounting policies adopted are consistent with those applied for the 2017 Annual Report and should be read in conjunction with that Annual Report. The interim report provides alternative performance measures for monitoring the Group's operations. Percentual changes and key figures in the report have been calculated based on the rounded amounts as presented in the report. Unless otherwise specified, all figures pertain to SEK M and figures in parentheses pertain to the year-earlier period.

### *New accounting policies*

The Group has assessed the effects of the implementation of IFRS 9 Financial instruments and IFRS 15 Revenue from Contracts with Customers and has concluded that there are no material differences between these new standards and the accounting policies previously applied by the Group as regards the recognition and measurement of financial instruments, impairment of doubtful receivables and revenue recognition. Accordingly, the introduction of IFRS 9 and IFRS 15, which apply from January 1, 2018, did not impact the Group's equity. The Group is currently assessing the full impact of implementing the standard IFRS 16 Leases that comes into force on January 1, 2019. At this stage, the Group does not intend to apply the standard earlier than the effective date. For more information about these new standards, refer to page 75 in the 2017 Annual Report.

### *Restated segment information*

Getinge reports Life Science as a new business area from January 1, 2018, and segment information for 2017 was thus restated. Life Science was previously part of the Surgical Workflows business area.

### *Reclassification of costs*

Costs the 2017 comparative year were reclassified between cost of goods sold and administrative expenses to reflect organizational changes in functions including Quality and IT. These reclassifications entail that cost of goods sold declined by SEK 50 M in the first quarter of 2017 and SEK 60 M in the second quarter of the same year. The decline in the cost of goods sold for the full-year 2017 thus amounted to SEK 110 M. Administrative expenses increased at a corresponding amount. The reclassifications affect only the Surgical Workflows business area.

### *Change in accounting policy for the Parent Company*

The Parent Company changed its accounting policy for Group contributions in 2018. Group contributions paid and received are now recognized as appropriations according to the alternative rule in RFR 2 and for this reason Group contributions were reclassified from Result from participations in Group companies to Appropriations.

### *Distribution of Arjo*

The distribution of Arjo in December 2017 is recognized in this report in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations. Net profit for the period for the discontinued operations is recognized separately in the consolidated income statement under the item "Net profit for the period from discontinued operations." This means that income and expenses for Arjo are excluded from other income-statement items for all reported periods. The discontinued operations were not separated in the consolidated cash flow statement. Cash flow disclosures for these operations are instead recognized in Note 9. Only assets and liabilities remaining in the Group after the distribution of Arjo are recognized in the balance sheet, meaning that Arjo is included in the balance sheet as per June 30, 2017.



## Note 2 Segment overview

	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Net sales, SEK M</b>					
Acute Care Therapies	3,148	3,094	5,999	5,919	12,201
Life Science	550	406	992	867	1,947
Surgical Workflows	2,033	1,869	3,608	3,394	8,347
<b>Total</b>	<b>5,731</b>	<b>5,369</b>	<b>10,599</b>	<b>10,180</b>	<b>22,495</b>
<b>Gross profit, SEK M</b>					
Acute Care Therapies	1,732	1,766	3,365	3,401	6,787
Life Science	186	164	362	340	749
Surgical Workflows	736	714	1,331	1,331	3,176
<b>Total</b>	<b>2,654</b>	<b>2,644</b>	<b>5,058</b>	<b>5,072</b>	<b>10,712</b>
<b>Operating profit (EBIT), SEK M</b>					
Acute Care Therapies	477	12	632	417	1,131
Life Science	51	64	107	166	364
Surgical Workflows	-52	16	-363	-140	211
Group functions and other (incl. eliminations) <sup>1)</sup>	-71	-50	-132	-99	-213
<b>Operating profit (EBIT)</b>	<b>405</b>	<b>42</b>	<b>244</b>	<b>344</b>	<b>1,493</b>
Net financial items	-74	-158	-195	-301	-560
<b>Profit/loss after financial items</b>	<b>331</b>	<b>-116</b>	<b>49</b>	<b>43</b>	<b>933</b>

1) Group functions and other refer mainly to central functions such as finance, communication, HR and other items, such as eliminations.

## Note 3 Depreciation, amortization and write-downs

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Intangible assets in acquired companies	-120	-149	-231	-304	-586
Intangible assets	-180	-188	-361	-370	-943
Tangible assets	-115	-108	-224	-217	-437
<b>Total</b>	<b>-415</b>	<b>-445</b>	<b>-816</b>	<b>-891</b>	<b>-1,966</b>
<i>of which write-downs</i>	-	-1	-	-2	-203
<b>SEK M</b>					
Cost of goods sold	-190	-184	-374	-366	-891
Selling expenses	-138	-170	-267	-342	-661
Administrative expenses	-80	-83	-161	-168	-333
Research and development costs	-7	-7	-14	-13	-26
Restructuring costs	-	-1	-	-2	-55
<b>Total</b>	<b>-415</b>	<b>-445</b>	<b>-816</b>	<b>-891</b>	<b>-1,966</b>
<i>of which write-downs</i>	-	-1	-	-2	-203

## Note 4 Quarterly results

SEK M	Apr-Jun 2018	Jan-Mar 2018	Oct-Dec 2017	Jul-Sep 2017	Apr-Jun 2017	Jan-Mar 2017	Oct-Dec 2016	Jul-Sep 2016
Net sales	5,731	4,868	7,371	4,944	5,369	4,811	7,434	5,087
Cost of goods sold	-3,077	-2,464	-4,179	-2,496	-2,725	-2,383	-4,036	-2,604
<b>Gross profit</b>	<b>2,654</b>	<b>2,404</b>	<b>3,192</b>	<b>2,448</b>	<b>2,644</b>	<b>2,428</b>	<b>3,398</b>	<b>2,483</b>
Operating expenses	-2,249	-2,565	-2,347	-2,144	-2,602	-2,126	-2,090	-2,645
<b>Operating profit/loss (EBIT)</b>	<b>405</b>	<b>-161</b>	<b>845</b>	<b>304</b>	<b>42</b>	<b>302</b>	<b>1,308</b>	<b>-162</b>
Net financial items	-74	-121	-127	-132	-158	-143	-127	-132
<b>Profit/loss after financial items</b>	<b>331</b>	<b>-282</b>	<b>718</b>	<b>172</b>	<b>-116</b>	<b>159</b>	<b>1,181</b>	<b>-294</b>
Taxes	-240	-19	242	-47	31	-42	-309	78
<b>Net profit/loss for the period from continuing operations</b>	<b>91</b>	<b>-301</b>	<b>960</b>	<b>125</b>	<b>-85</b>	<b>117</b>	<b>872</b>	<b>-216</b>

## Note 5 Adjustment items

Adjusted EBITA, SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Acute Care Therapies	596	638	1,066	1,195	2,500
Life Science	52	64	109	168	369
Surgical Workflows	-39	49	-204	-78	445
Group functions and other (incl. eliminations)	-71	-49	-132	-98	-206
<b>Total, Group</b>	<b>538</b>	<b>702</b>	<b>839</b>	<b>1,187</b>	<b>3,108</b>

Adjustments of EBITA, SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Specification of items affecting comparability</b>					
Acquisition and restructuring costs, Acute Care Therapies	-8	-492	-9	-502	-607
Acquisition and restructuring costs, Life Science	-	-	-	-2	-2
Acquisition and restructuring costs, Surgical Workflows	-5	-18	-5	-34	-147
Write-down of inventories, Acute Care Therapies <sup>1)</sup>	-	-	-	-	-17
Write-down of R&D, Acute Care Therapies <sup>1)</sup>	-	-	-	-	-122
Write-down of inventories, Surgical Workflows <sup>1)</sup>	-	-	-	-	-32
Write-down of R&D, Surgical Workflows <sup>1)</sup>	-	-	-	-	-26
Provision for ongoing investigation in Brazil, Acute Care Therapies <sup>2)</sup>	-	-	-210	-	-69
Provision for ongoing investigation in Brazil, Surgical Workflows <sup>2)</sup>	-	-	-140	-	-
Group functions and other (incl. eliminations)	-	-1	-	-1	-7
<b>Total, Group</b>	<b>-13</b>	<b>-511</b>	<b>-364</b>	<b>-539</b>	<b>-1,029</b>

Items affecting comparability per segment	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Acute Care Therapies	-8	-492	-219	-502	-815
Life Science	-	-	-	-2	-2
Surgical Workflows	-5	-18	-145	-34	-205
Group functions and other (incl. eliminations)	-	-1	-	-1	-7
<b>Total, Group</b>	<b>-13</b>	<b>-511</b>	<b>-364</b>	<b>-539</b>	<b>-1,029</b>

1) Reported in Cost of goods sold

2) Reported in Other operating income and operating expenses

EBITA, SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Acute Care Therapies	588	146	847	693	1,685
Life Science	52	64	109	166	367
Surgical Workflows	-44	31	-349	-112	240
Group functions and other (incl. eliminations)	-71	-50	-132	-99	-213
<b>Total, Group</b>	<b>525</b>	<b>191</b>	<b>475</b>	<b>648</b>	<b>2,079</b>

Adjustment of tax, SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Amortization and write-down of acquired intangible assets	120	149	231	304	586
Items affecting comparability	13	511	364	539	1,029
<b>Adjustment items, total</b>	<b>133</b>	<b>660</b>	<b>595</b>	<b>843</b>	<b>1,615</b>
Tax effect on adjustment items <sup>1)</sup>	-36	-178	-66	-228	-436
Tax items affecting comparability <sup>2)</sup>	152	-	152	-	-302
<b>Total, Group</b>	<b>116</b>	<b>-178</b>	<b>86</b>	<b>-228</b>	<b>-738</b>

1) Standard tax of 27% on taxable deductible adjustment items

2) 2018: Provision of SEK 64 M for self correction of tax return related to ongoing investigations in Brazil and SEK 88 in tax effect due to the tax rate change in Sweden. The effects in 2017 refer to the US Tax Reform.

## Note 6 Consolidated net interest-bearing debt

SEK M	June 30 2018	June 30 2017	December 31 2017
Other interest-bearing liabilities	11,562	20,897	11,237
Provisions for pensions, interest-bearing	3,222	3,169	3,081
<b>Interest-bearing liabilities</b>	<b>14,784</b>	<b>24,066</b>	<b>14,318</b>
Less cash and cash equivalents	-939	-1,400	-1,526
<b>Net interest-bearing debt</b>	<b>13,845</b>	<b>22,666</b>	<b>12,792</b>

## Note 7 Key figures for the Group

Financial and operative key figures	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Key figures based on Getinge's financial targets</b>					
Organic growth in net sales, %	6.0	-0.5	5.7	1.0	1.3
Earnings per share <sup>1)</sup> , SEK	0.30	-0.37	-0.83	0.10	4.37
<b>Other operative and financial key figures</b>					
Organic growth in order intake, %	10.2	-6.7	6.7	-2.6	2.5
Gross margin, %	46.3	49.2	47.7	49.8	47.6
Selling expenses, % of net sales	22.3	23.4	23.8	24.6	22.1
Administrative expenses, % of net sales	13.3	12.4	14.2	13.8	12.3
Research and development costs, % of net sales	6.0	5.5	6.3	5.6	5.0
Operating margin, %	7.1	0.8	2.3	3.4	6.6
EBITDA, SEK M	820	487	1,060	1,235	3,459
Number of shares <sup>2)</sup> , thousands	272,370	241,780	272,370	241,780	250,720
Number of shares at the end of the period <sup>2)</sup> , thousands	272,370	241,780	272,370	241,780	272,370
Interest-coverage ratio, multiple			8.9	7.4	8.6
Net debt/equity ratio <sup>3)</sup> , multiple			0.67	N/A	0.65
Net debt/Rolling 12m adjusted EBITDA <sup>3)</sup> , multiple			3.5	N/A	3.0
Return on equity <sup>3)</sup> , %			4.3	N/A	6.6
Equity/assets ratio, %			47.6	38.0	47.0
Equity per share <sup>3)</sup> , SEK			75.88	N/A	72.72
Number of employees			10,748	10,617	10,684

1) Before and after dilution

2) Adjusted for bonus issue effect of the rights issue

3) Not applicable due to the distribution of Arjo in December 2017

## Alternative performance measures

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. The alternative performance measures are not to be considered a substitute for, but rather a supplement to, the financial statements prepared in accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies.

	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Adjusted gross profit, SEK M</b>					
<b>Gross profit</b>	<b>2,654</b>	<b>2,644</b>	<b>5,058</b>	<b>5,072</b>	<b>10,712</b>
<i>Add-back of:</i>					
Depreciation, amortization and write-downs of intangible and tangible assets	190	184	374	366	891
Other items affecting comparability	-	-	-	-	197
Adjustment for write-downs included in other items affecting comparability	-	-	-	-	-148
<b>Adjusted gross profit</b>	<b>2,844</b>	<b>2,828</b>	<b>5,432</b>	<b>5,438</b>	<b>11,652</b>

	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Adjusted EBITDA, SEK M</b>					
<b>Operating profit (EBIT)</b>	<b>405</b>	<b>42</b>	<b>244</b>	<b>344</b>	<b>1,493</b>
<i>Add-back of:</i>					
Depreciation, amortization and write-downs of intangible and tangible assets	295	296	585	587	1,380
Amortization and write-down of acquired intangible assets	120	149	231	304	586
Other items affecting comparability	-	-	350	-	266
Acquisition and restructuring costs	13	511	14	539	763
Adjustment for write-downs included in other items affecting comparability and restructuring costs	-	-1	-	-2	-203
<b>Adjusted EBITDA</b>	<b>833</b>	<b>997</b>	<b>1,424</b>	<b>1,772</b>	<b>4,285</b>

	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Adjusted EBITA, SEK M</b>					
<b>Operating profit (EBIT)</b>	<b>405</b>	<b>42</b>	<b>244</b>	<b>344</b>	<b>1,493</b>
<i>Add-back of:</i>					
Amortization and write-down of acquired intangible assets	120	149	231	304	586
Other items affecting comparability	-	-	350	-	266
Acquisition and restructuring costs	13	511	14	539	763
<b>Adjusted EBITA</b>	<b>538</b>	<b>702</b>	<b>839</b>	<b>1,187</b>	<b>3,108</b>

	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Adjusted EBIT, SEK M</b>					
<b>Operating profit (EBIT)</b>	<b>405</b>	<b>42</b>	<b>244</b>	<b>344</b>	<b>1,493</b>
<i>Add-back of:</i>					
Other items affecting comparability	-	-	350	-	266
Acquisition and restructuring costs	13	511	14	539	763
<b>Adjusted EBIT</b>	<b>418</b>	<b>553</b>	<b>608</b>	<b>883</b>	<b>2,522</b>

	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
<b>Adjusted net profit/loss for the period from continuing operations, SEK M</b>					
<b>Net profit for the period from continuing operations</b>	<b>91</b>	<b>-85</b>	<b>-210</b>	<b>32</b>	<b>1,117</b>
<i>Add-back of:</i>					
Amortization and write-down of acquired intangible assets	120	149	231	304	586
Other items affecting comparability	-	-	350	-	266
Acquisition and restructuring costs	13	511	14	539	763
Tax items affecting comparability	152	-	152	-	-302
Tax on add-back items	-36	-178	-66	-228	-436
<b>Adjusted net profit for the period from continuing operations</b>	<b>340</b>	<b>397</b>	<b>471</b>	<b>647</b>	<b>1,994</b>

## Note 8 Acquisitions

No acquisitions took place the second quarter.

## Note 9 Discontinued operations

### Distribution and listing of Arjo

Arjo was distributed to the shareholders of Getinge AB and listed on Nasdaq Stockholm on December 12, 2017. In this report, Arjo is recognized as a discontinued operation in the consolidated income statement with retrospective effect for prior periods and in accordance with IFRS 5.

Income statement for discontinued operations, SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Net sales	-	1,894	-	3,825	6,929
Cost of goods sold	-	-1,029	-	-2,043	-3,863
<b>Gross profit</b>	-	<b>865</b>	-	<b>1,782</b>	<b>3,066</b>
Selling expenses	-	-395	-	-778	-1,425
Administrative expenses	-	-303	-	-490	-992
Research and development costs	-	-29	-	-64	-118
Restructuring costs	-	-15	-	-84	-250
Other operating income and expenses	-	-3	-	-8	13
<b>Operating profit (EBIT)</b>	-	<b>120</b>	-	<b>358</b>	<b>294</b>
Net financial items	-	5	-	-9	-84
<b>Profit after financial items</b>	-	<b>125</b>	-	<b>349</b>	<b>210</b>
Taxes	-	-33	-	-93	-57
<b>Net profit for the period from the operations</b>	-	<b>92</b>	-	<b>256</b>	<b>153</b>
Profit from translation differences and hedges	-	-	-	-	127
<b>Net profit for the period</b>	-	<b>92</b>	-	<b>256</b>	<b>280</b>

Cash flow from discontinued operations, SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Cash flow from operating activities	-	122	-	275	269
Cash flow from investing activities	-	-102	-	-192	-320
Cash flow from financing activities	-	-11	-	-9	4
<b>Cash flow for the period</b>	-	<b>9</b>	-	<b>74</b>	<b>-47</b>

## Parent Company financial statements

### Parent Company's income statement

SEK M	Apr-Jun 2018	Apr-Jun 2017	Jan-Jun 2018	Jan-Jun 2017	Jan-Dec 2017
Administrative expenses	-117	-71	-236	-195	-251
Other operating expenses	-301	-	-301	-	-
<b>Operating result</b>	<b>-418</b>	<b>-71</b>	<b>-537</b>	<b>-195</b>	<b>-251</b>
Result from participations in Group companies <sup>1)</sup>	8,217	1,959	8,217	1,959	2,859
Interest income and other similar income	205	799	205	1,158	1,614
Interest expenses and other similar expenses	-865	-140	-1,361	-282	-574
<b>Profit after financial items<sup>2)</sup></b>	<b>7,139</b>	<b>2,547</b>	<b>6,524</b>	<b>2,640</b>	<b>3,648</b>
Appropriations	-	-	-	-	-420
Taxes	140	-25	276	-47	-99
<b>Net profit for the period<sup>3)</sup></b>	<b>7,279</b>	<b>2,522</b>	<b>6,800</b>	<b>2,593</b>	<b>3,129</b>

- 1) Internal restructuring took place in the quarter, resulting in a liquidation result of SEK 8,217 M in the Parent Company, which is recognized under Result from participations in Group companies.
- 2) Interest income and other similar income and interest expenses and other similar expenses include exchange-rate gains and losses attributable to the translation of receivables and liabilities in foreign currencies measured
- 3) Comprehensive income for the period corresponds to net profit for the period

### Parent Company's balance sheet

SEK M	June 30 2018	June 30 2017	December 31 2017
<b>Assets</b>			
Intangible assets	85	98	86
Tangible assets	10	5	6
Participations in Group companies	33,692	27,364	25,455
Deferred tax assets	462	183	189
Long-term receivables	57	-	53
Receivables from Group companies	30	5,255	953
Current receivables	239	196	191
<b>Total assets</b>	<b>34,575</b>	<b>33,101</b>	<b>26,933</b>
<b>Equity and liabilities</b>			
Equity	18,975	11,676	12,584
Long-term liabilities	5,693	11,098	4,257
Long-term liabilities to Group companies	717	-	659
Current liabilities to Group companies	4,551	527	2,990
Current liabilities	4,639	9,800	6,443
<b>Total equity and liabilities</b>	<b>34,575</b>	<b>33,101</b>	<b>26,933</b>

## Definitions

### Financial terms

**Return on equity.** Rolling 12 months' profit after tax in relation to average equity.

**Gross margin.** Gross profit in relation to net sales.

**Adjusted gross profit.** Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.

**EBIT.** Operating profit.

**Adjusted EBIT.** Operating profit with add-back of acquisition and restructuring costs and other items affecting comparability.

**EBITA.** Operating profit before depreciation and write-down of acquired intangible assets.

**Adjusted EBITA.** EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.

**EBITA margin.** EBITA in relation to net sales.

**EBITDA.** Operating profit before depreciation, amortization and write-down.

**Adjusted EBITDA.** EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.

**EBITDA margin.** EBITDA in relation to net sales.

**Equity per share, SEK.** Equity in relation to the number of shares at the end of the period.

**Cash flow after net investments.** Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations.

**Net debt/equity ratio.** Net interest-bearing debt in relation to equity.

**Organic change.** A change in percentage adjusted for currency, acquisitions and divestments in the past period compared with the year-earlier period.

**Adjusted net profit for the period.** Net profit for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income-statement items.

**Adjusted profit before tax** Profit before tax for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.

**Earnings per share.** Net profit for the period attributable to Parent Company shareholders in relation to average number of shares.

**Adjusted earnings per share.** Adjusted net profit for the period attributable to Parent Company shareholders in relation to average number of shares.

**Interest-coverage ratio.** Rolling 12 months' adjusted EBITDA in relation to rolling 12 months' net interest.

**Operating margin.** Operating profit (EBIT) in relation to net sales.

**Equity/assets ratio.** Equity in relation to total assets.

**Currency transaction effect.** Exchange of current year's volumes of foreign currency at this year's exchange rates, compared

with the exchange rates in the preceding year.

### Medical terms

**Sterilizer.** A device to destroy microorganisms on surgical instruments, usually by bringing to a high temperature with steam.

**Cardiopulmonary.** Pertaining or belonging to both heart and lung.

**Cardiovascular.** Pertaining or belonging to both heart and blood vessels.

**Endoscope.** Equipment for visual examination of the body's cavities, such as the stomach.

**Endovascular.** Vascular treatment using catheter technologies.

**Artificial grafts.** Artificial vascular implants.

**Low temperature sterilization.** A device used to sterilize surgical instruments which cannot be sterilized with high temperature steam. It is mainly used for instruments used in the minimal invasive and robotic surgery.

**Stent.** A tube for endovascular widening of blood vessels.

**Vascular intervention.** A medical procedure conducted through vascular puncturing instead of using an open surgery method.

### Geographical areas

**Americas.** North, South and Central America.

**APAC.** Asia and Pacific.

**EMEA.** Europe, Middle East and Africa.

## Teleconference

Teleconference with President & CEO Mattias Perjos and CFO Lars Sandström on July 17, 2018 at 10:00-11:00 a.m. CEST. Please see dial in details below to join the conference:

SE: +46 8 56642697  
UK: +44 2030089807  
US: +1 8558315947

A presentation will be held during the telephone conference. To access the presentation, please use this link:

<https://tv.streamfabriken.com/getinge-q2-2018>

Alternatively, use the following link to download the presentation: <https://www.getinge.com/int/about-us/investors/reports-presentations/2018/>

A recording of the teleconference will be available for 3 days via the following link: <https://tv.streamfabriken.com/getinge-q2-2018>

## Financial information

Updated information on, for example, the Getinge share and corporate governance is available on Getinge's website [www.getinge.com](http://www.getinge.com). The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at [www.getinge.com](http://www.getinge.com). The following dates have been set for the publication of financial communication for the remainder of 2018 and 2019:

October 18, 2018	Interim report January–September
November 21, 2018	Capital Markets Day
January 30, 2019	Year-End Report 2018
March 2019	2018 Annual Report

## Contact

Jeanette Hedén Carlsson, Executive Vice President, Communications & Brand Management  
+46 (0) 10 335 1003  
[Jeanette.hedencarlsson@getinge.com](mailto:Jeanette.hedencarlsson@getinge.com)

Lars Mattsson, Head of Investor Relations  
+46 (0)10 335 0043  
[lars.mattsson@getinge.com](mailto:lars.mattsson@getinge.com)

This information is such that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CEST on July 17, 2018.

**Getinge AB (publ)**  
Lindholmspiren 7  
SE-417 56 Gothenburg  
Sweden

Tel: +46 (0)10 335 0000  
E-mail: [info@getinge.com](mailto:info@getinge.com)  
Corporate registration number: 556408-5032  
[www.getinge.com](http://www.getinge.com)